Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis. 

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Doctors

Maintenance and Care

Targeted Therapy

The maintenance phase of targeted therapy is different from recovery after chemotherapy. Targeted drugs usually stop cancer from growing rather than killing it, so treatment often continues for a long time or even indefinitely. Living with cancer becomes a managed, ongoing condition. The main goal is to keep quality of life high while controlling the cancer. This means actively managing ongoing mild side effects that can add up over time.

Monitoring during targeted therapy is ongoing and includes checking for both tumor growth and new resistance mutations. Cancer cells can change and develop new mutations that make the drug stop working. Regular tests, like liquid biopsies, can find these changes early, sometimes before the tumor grows again. This lets doctors switch to a new drug sooner and keep the cancer under control longer.

Managing Chronic Toxicities

image 2 3507 LIV Hospital

Long-term mild side effects from targeted therapy, like rash, dry skin, diarrhea, or mouth sensitivity, can be tiring and make it hard for patients to keep taking their medicine. Ongoing care includes using special creams, moisturizers, and antibiotics for the skin, and managing stomach issues with diet changes and anti-diarrheal medicine. The main challenge is dealing with the daily burden of these side effects, and the solution is supportive care to help patients stay on treatment.

Cardiovascular and Metabolic Stewardship

Global Biotechnological Perspectives

Long-term use of drugs that block VEGF or HER2 means patients need careful heart and blood vessel monitoring. Those on anti-angiogenic therapy must keep their blood pressure under control to avoid kidney damage or stroke. Patients on metabolic inhibitors need to manage high blood sugar and cholesterol to prevent heart disease. Ongoing care uses heart and hormone health strategies to protect organs affected by treatment.

Psychosocial and Lifestyle Adaptation

The Regenerative Context and Microenvironment Modulation

Living with cancer as a long-term condition brings its own emotional challenges. Patients may take daily medication for years, which can cause anxiety about the cancer coming back or the treatment stopping working. Support for mental health is important to help patients handle this uncertainty. Healthy habits like exercise and good nutrition are also encouraged, as they can improve overall health and may help the treatment work better.

Long-Term Surveillance Technologies

  • Molecular Monitoring: Periodic blood tests for ctDNA to track the clonal evolution of the tumor and detect resistance mutations early.
  • Echocardiography: Routine interval scanning for patients on HER2 or TKI therapy to monitor for subclinical declines in cardiac contractility.
  • Dermatological Surveillance: Regular whole body skin exams for patients on BRAF inhibitors due to the risk of secondary cutaneous squamous cell carcinomas.
  • Metabolic Panels: Quarterly monitoring of HbA1c and lipid profiles for patients on PI3K/mTOR pathway inhibitors.
  • Thyroid Function Testing: Ongoing TSH monitoring for patients on multikinase inhibitors to manage drug-induced hypothyroidism.
  • Quality of Life Assessment: Validated tools to track patient-reported outcomes, ensuring that the toxicity of the cure does not outweigh the benefit of disease control.

Regenerative Therapies in Survivorship

Regenerative medicine can help manage skin and nail problems caused by targeted therapy. Researchers are testing special serums and treatments made from the patient’s own blood to heal skin cracks and nail changes from EGFR inhibitors. These treatments are used only on the skin, not throughout the body, to avoid helping the tumor. For rare jaw problems caused by bone drugs, regenerative techniques using plasma can help the mouth heal.

The Future of Maintenance: Drug Holidays and Intermittent Dosing

An emerging concept in maintenance is the “drug holiday.” Preclinical models suggest that continuous high-dose therapy selects for resistant cells. Intermittent dosing strategies are being tested to see if “pulsing” the drug can maintain tumor control while delaying resistance and giving the patient a physiological and psychological break. This adaptive therapy approach represents the future of maintenance, treating the tumor as an evolving ecosystem rather than a static target.

30 Years of
Excellence

Trusted Worldwide

With patients from across the globe, we bring over three decades of medical

Book a Free Certified Online
Doctor Consultation

Clinics/branches

Was this article helpful?

Was this article helpful?

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Doctors

FREQUENTLY ASKED QUESTIONS

What is “acquired resistance”?

Acquired resistance occurs when a targeted therapy that was previously effective stops working. This happens because cancer cells evolve and develop new mutations that allow them to bypass the drug’s mechanism of action. It’s a common challenge in long-term treatment, and monitoring for it is a key part of maintenance care.

Generally, targeted therapies are designed to be taken continuously to keep the cancer suppressed. Stopping the drug (“drug holiday”) can allow the tumor to flare up rapidly. However, if side effects become severe, your doctor may recommend a short, supervised break to allow your body to recover before restarting, often at a lower dose.

The rash from targeted therapy (such as EGFR inhibitors) is not acne and shouldn’t be treated with acne creams, which can further dry the skin. Management involves keeping the skin moist with alcohol-free creams, using sunscreen, taking warm (not hot) showers, and using prescription steroid creams or oral antibiotics prescribed by your oncology team.

In the metastatic setting, targeted therapy is typically continued indefinitely as long as it is controlling the cancer. It is considered a chronic treatment. In the adjuvant setting (after surgery to prevent recurrence), it is usually given for a specific period, such as 1 to 3 years, depending on the drug and cancer type.

“Scanxiety” is the stress and anxiety patients feel before undergoing follow-up scans to check if the cancer is still stable. For patients on long-term targeted therapy, this is a recurring emotional hurdle. Coping strategies include support groups, mindfulness techniques, and open communication with the medical team about fears and expectations.

Spine Hospital of Louisiana

Let's Talk About Your Health

BUT WAIT, THERE'S MORE...

Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.

Let's Talk About Your Health

Let's Talk About Your Health

Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.

Let's Talk About Your Health

How helpful was it?

helpful
helpful
helpful
Your Comparison List (you must select at least 2 packages)